Andrew Whynot

Andrew Whynot has extensive work experience in the pharmaceutical and biotechnology industry. Andrew currently serves as the Senior Director of CMC Operations at Beam Therapeutics since 2022. Prior to that, they held various roles at Intellia Therapeutics, Inc., including Director of CMC Strategy and Operations and Head of CMC Project Management between 2020 and 2022.

Before joining Intellia Therapeutics, Andrew worked at Solid Biosciences from 2017 to 2020, where they held positions such as Director of Process Development Project Management, Associate Director of Process Development Project Management, Senior Project Manager of Process Development, and Project Manager of Process Development.

Andrew also has experience in business development, serving as the Director of Business Development at Calvert Labs from 2016 to 2017 and as a Business Development Associate at Chemic Laboratories Inc. from 2013 to 2016.

Andrew's earlier experience includes working as a Graduate Student at Harvard University from 2009 to 2011 and as a Research Assistant at Harvard Medical School from 2005 to 2009. Andrew also worked as a Research Intern at Cornell University Shoals Marine Lab in 2005.

Andrew Whynot's education history includes:

- From 2001 to 2005, they attended the University of Massachusetts Amherst, where they obtained a Bachelor of Science degree in Biology.

- From 2009 to 2011, they attended Harvard University and studied Biochemistry.

- There is no available information about their education prior to university.

In addition to their formal education, Andrew Whynot has obtained multiple certifications in project management from LinkedIn, including Agile Project Management Foundations, Become a Project Manager, Microsoft Project 2016 Essential Training, and several others.